Trial Profile
A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 and 400 mcg o.d.) in patients with chronic obstructive pulmonary disease using formoterol (12 mcg b.i.d.) as an active control.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 26 Jul 2020 Status changed from recruiting to completed.
- 23 May 2011 This trial is recruiting in Great Britain and has completed in Germany and discontinued in Sweden.
- 17 May 2011 New trial record